nature portfolio

Corresponding author(s):	Bernd Nidetzky
Last updated by author(s):	Jun 5, 2024

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

_					
C:	トつ	11	ist	11	\sim
			ורו		

For a	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	$oxed{\boxtimes}$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🔀 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
\boxtimes	A description of all covariates tested
\boxtimes	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
\boxtimes	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
\boxtimes	\square Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated
	Our walk as the string are statistics for high sints and since or string and the second state of the secon

Software and code

Policy information about availability of computer code

Data collection

Chromeleon Client v6.80 was used for preparative HPLC and ChemStation Rev. B.04.03-SP2 for HPLC-UV/MS and HPLC-UV operation. Jeol Delta 6.1 and Bruker Topspin 3.5 softwares were used for NMR measurements.

Data analysis

The ProtParam tool of Expasy was used for calculation of the molecular weight and molar extinction coefficient of enzymes used. ChemStation Rev. B.04.03-SP2 (Agilent) was used for HPLC-UV/MS and HPLC-UV data analysis; Chromeleon Client v6.80 for preparative HPLC data analysis. MestReNova 16.0 (Mestrelab Research, S.L.) and JASON v3.1 (Jeol) were used for NMR spectra interpretation. SigmaPlot v10.0 was used for nonlinear fitting of initial rate data. AlphaFold DB was used for structural prediction and Pymol v4.6 for structural analysis of proteins.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio <u>guidelines for submitting code & software</u> for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All relevant data are reported in the manuscript and in the associated Supplementary Information. All data are available from the corresponding author upon request. There is no restriction on data availability. Sequence information on proteins used within this study is available on the UniProt database (https://www.uniprot.org/). UGT84A49, UGT84A119, UGT72D1 and UGT72D7 are registered under accession numbers Q2V6K1 [https://www.uniprot.org/uniprotkb/Q2V6K1/entry], A0A2N9FYZ7 [https://www.uniprot.org/uniprotkb/A0A2N9FYZ7/entry], Q9ZU72 [https://www.uniprot.org/uniprotkb/Q9ZU72/entry] and A0A067GVI4 [https://www.uniprot.org/uniprotkb/A0A067GVI4/entry], respectively.

Research involving human participants, their data, or biological material

Policy information about studies with <u>human participants or human data</u>. See also policy information about <u>sex, gender (identity/presentation)</u>, <u>and sexual orientation</u> and <u>race, ethnicity and racism</u>.

and recovered and recovered and recovered		
Reporting on sex and gender	N/A	
Reporting on race, ethnicity, or other socially relevant groupings	N/A	
Population characteristics	N/A	
Recruitment	N/A	
Ethics oversight	N/A	

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.			
∑ Life sciences [Behavioural & social sciences		
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf			

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	The study was performed with purified enzymes. The sample size "n" is given in each experiment. Kinetic measurements were conducted in three individual experiments. The n= employed is the standard for biochemical protein characterization.	
Data exclusions	ons No data was excluded from the analysis.	
Replication	Kinetic studies were conducted in three individual experiments. All attempts of replication were successful, leading to the calculation of consistent kinetic parameters.	
Randomization	Randomization is not typically applied in enzyme kinetics determinations/biocatalysis assays.	
Blinding	Blinding is not typically applied in enzyme kinetics determinations/biocatalysis assays.	

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems		Methods	
n/a	Involved in the study	n/a	Involved in the study
\boxtimes	Antibodies	\boxtimes	ChIP-seq
\boxtimes	Eukaryotic cell lines	\boxtimes	Flow cytometry
\boxtimes	Palaeontology and archaeology	\boxtimes	MRI-based neuroimaging
\boxtimes	Animals and other organisms		
\boxtimes	Clinical data		
\boxtimes	Dual use research of concern		
\boxtimes	Plants		